-
-
-
-
-
-
-
Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
-
-
-
-
-
-
-
Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
-
-
-
-
-
-
-
Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
-
-
-
-
-
-
-
Clearmind Medicine (CMND) Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
-
-
-
-
-
-
-
Clearmind Medicine Announces Pricing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
-
-
-
-
-
-
-
Yale’s Department of Psychiatry Chair to Join Clearmind Medicine
-
-
-
-
-
-
-
Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

